Xeris Taps CEO to Additionally Serve as Chairman

Dow Jones06-30

Xeris Biopharma said its board appointed John Shannon as chairman, effective July 1, nearly two years after he assumed the role of chief executive.

Shannon succeeds Marla Persky as chair of the board, though Persky will remain on the board as lead independent director, the biopharmaceutical company said Tuesday.

"When John was appointed CEO, the board wanted him to focus on strategy and growth," Persky said. She added that in the time since, he has clearly demonstrated the leadership and vision necessary to advance the company.

"His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman," she said.

Shannon joined Xeris in 2017 as chief operating officer. He was previously promoted to president in 2020.

Xeris also on Tuesday appointed Nerissa Kreher to its board, expanding it to eight members.

Kreher currently serves as chief medical officer of Alltrna, where she leads clinical development, regulatory and patient advocacy, Xeris said.

She has more than two decades of experience, having previously held leadership roles at companies including Entrada Therapeutics, Tiburio Therapeutics and AvroBio.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

June 30, 2026 08:10 ET (12:10 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2647555385?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 20:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2647555385","market":"nz","top_or_hot":-1,"title":"Xeris Taps CEO to Additionally Serve as Chairman","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Xeris Biopharma said its board appointed John Shannon as chairman, effective July 1, nearly two years after he assumed the role of chief executive. \n</p>\n<p>\n  Shannon succeeds Marla Persky as chair of the board, though Persky will remain on the board as lead independent director, the biopharmaceutical company said Tuesday. \n</p>\n<p>\n  \"When John was appointed CEO, the board wanted him to focus on strategy and growth,\" Persky said. She added that in the time since, he has clearly demonstrated the leadership and vision necessary to advance the company. \n</p>\n<p>\n  \"His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman,\" she said. \n</p>\n<p>\n  Shannon joined Xeris in 2017 as chief operating officer. He was previously promoted to president in 2020. \n</p>\n<p>\n  Xeris also on Tuesday appointed Nerissa Kreher to its board, expanding it to eight members. \n</p>\n<p>\n  Kreher currently serves as chief medical officer of Alltrna, where she leads clinical development, regulatory and patient advocacy, Xeris said. \n</p>\n<p>\n  She has more than two decades of experience, having previously held leadership roles at companies including Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Tiburio Therapeutics and AvroBio. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 08:10 ET (12:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Xeris Taps CEO to Additionally Serve as Chairman</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nXeris Taps CEO to Additionally Serve as Chairman\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-06-30 20:10</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Xeris Biopharma said its board appointed John Shannon as chairman, effective July 1, nearly two years after he assumed the role of chief executive. \n</p>\n<p>\n  Shannon succeeds Marla Persky as chair of the board, though Persky will remain on the board as lead independent director, the biopharmaceutical company said Tuesday. \n</p>\n<p>\n  \"When John was appointed CEO, the board wanted him to focus on strategy and growth,\" Persky said. She added that in the time since, he has clearly demonstrated the leadership and vision necessary to advance the company. \n</p>\n<p>\n  \"His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman,\" she said. \n</p>\n<p>\n  Shannon joined Xeris in 2017 as chief operating officer. He was previously promoted to president in 2020. \n</p>\n<p>\n  Xeris also on Tuesday appointed Nerissa Kreher to its board, expanding it to eight members. \n</p>\n<p>\n  Kreher currently serves as chief medical officer of Alltrna, where she leads clinical development, regulatory and patient advocacy, Xeris said. \n</p>\n<p>\n  She has more than two decades of experience, having previously held leadership roles at companies including Entrada <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, Tiburio Therapeutics and AvroBio. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 30, 2026 08:10 ET (12:10 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XERS","symbol_name":"Xeris制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2647555385","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2647555385","pubTimestamp":1782821400,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Xeris Biopharma said its board appointed John Shannon as chairman, effective July 1, nearly two years after he assumed the role of chief executive.Shannon succeeds Marla Persky as chair of the board, though Persky will remain on the board as lead independent director, the biopharmaceutical company said Tuesday.\"When John was appointed CEO, the board wanted him to focus on strategy and growth,\" Persky said. She added that in the time since, he has clearly demonstrated the leadership and vision necessary to advance the company.\"His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman,\" she said.Shannon joined Xeris in 2017 as chief operating officer. He was previously promoted to president in 2020.Xeris also on Tuesday appointed Nerissa Kreher to its board, expanding it to eight members.Kreher currently serves as chief medical officer of Alltrna, where she leads clinical development, regulatory an","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"XERS":"Xeris制药","BK4007":"制药"},"translate_title":"Xeris任命首席执行官兼任董事长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XERS":0.9},"content_text":"Xeris Biopharma said its board appointed John Shannon as chairman, effective July 1, nearly two years after he assumed the role of chief executive. \n\n\n  Shannon succeeds Marla Persky as chair of the board, though Persky will remain on the board as lead independent director, the biopharmaceutical company said Tuesday. \n\n\n  \"When John was appointed CEO, the board wanted him to focus on strategy and growth,\" Persky said. She added that in the time since, he has clearly demonstrated the leadership and vision necessary to advance the company. \n\n\n  \"His successes, combined with his deep understanding of the business, clearly demonstrate that John is the ideal person to now also serve as chairman,\" she said. \n\n\n  Shannon joined Xeris in 2017 as chief operating officer. He was previously promoted to president in 2020. \n\n\n  Xeris also on Tuesday appointed Nerissa Kreher to its board, expanding it to eight members. \n\n\n  Kreher currently serves as chief medical officer of Alltrna, where she leads clinical development, regulatory and patient advocacy, Xeris said. \n\n\n  She has more than two decades of experience, having previously held leadership roles at companies including Entrada Therapeutics, Tiburio Therapeutics and AvroBio. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 30, 2026 08:10 ET (12:10 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2647555385","isCrawlerRequest":true}